

Attorney Docket No.: **6478.1441-01**

Application No.: 09/880,887

Filing Date: June 15, 2001

Page 2

8. **(Twice Amended)** A process for the production of Factor VIII protein comprising:

- File
copy*
- a) preparing a modified Factor VIII cDNA wherein said Factor VIII cDNA is modified by replacement of the B-domain with nucleotides encoding four arginines and insertion of the truncated Factor IX intron 1 (SEQ ID NO: 9) in one or more splice sites of the Factor VIII cDNA;
 - b) introducing the modified Factor VIII cDNA into a cell; and
 - c) expressing the modified Factor VIII cDNA in said cell to produce Factor VIII protein.

REMARKS

Upon entry of this Supplemental Amendment, claims 7-11 are pending.

Applicants have amended claims 7 and 8 to correct a typographical error. Support for amended claims 7 and 8 can be found in the claims as originally filed and throughout the specification. Accordingly, no new matter has been added.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By: 

Sanya Pukdang
Reg. No. 46,390

Dated: June 4, 2003

541809-1

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER 
1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Attorney Docket No.: 6478.1441-01

Application No.: 09/880,887

Filing Date: June 15, 2001

Page 3

APPENDIX

Please amend claims 7 and 8 as follows:

7. **(Twice Amended)** A process for the production of Factor VIII protein comprising:

- a) preparing a modified Factor VIII cDNA wherein said Factor VIII cDNA is modified by deletion of the B-domain and insertion of the truncated **[Factor IX] Factor IX** intron 1 (SEQ ID NO: 9) in one or more splice sites of the Factor VIII cDNA;
- b) introducing the modified Factor VIII cDNA into a cell; and
- c) expressing the modified Factor VIII cDNA in said cell to produce Factor VIII protein.

8. **(Twice Amended)** A process for the production of Factor VIII protein comprising:

- a) preparing a modified Factor VIII cDNA wherein said Factor VIII cDNA is modified by replacement of the B-domain with nucleotides encoding four arginines and insertion of the truncated **[Factor IX] Factor IX** Intron 1 (SEQ ID NO: 9) in one or more splice sites of the Factor VIII cDNA;
- b) introducing the modified Factor VIII cDNA into a cell; and
- c) expressing the modified Factor VIII cDNA in said cell to produce Factor VIII protein.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202-408-4000
Fax 202-408-4400
www.finnegan.com

541809-1

Please Enter

JUN 04 2003 13:40 FR FINNEGAN HENDERSON 202 408 4400 TO 7037465312#

P. 01

**LAW OFFICES
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.**

1300 I Street, NW
Washington, DC 20005

Telephone
(202) 408-4000

Facsimile
(202) 408-4400

FACSIMILE TRANSMITTAL

TO

Name: Examiner Q. Nguyen
Group Art Unit 1632
Firm: USPTO
Fax No.: (703) 746-5312
Phone No.: (703) 308-8339
Date: June 4, 2003
Subject: Application No. 09/880,887

FROM

Name: Sanya Sukduang
Reg. #: 46,390
Phone No.: (202) 408-4377
Fax # Verified by: szs
Pages (incl. this): 4
Our File No.: 06478.1441-01000

Confirmation Copy to Follow: N

Message:

CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. § 1.8

I hereby certify that the attached paper, "Supplemental Amendment," is being transmitted by facsimile to the U.S. Patent and Trademark Office on the above-identified date.

Sanya Sukduang
Reg. No. 46,390

SZS/JFI

If there is a problem with this transmission, notify fax room at (202) 408-4174 or the sender at the number above.

This facsimile is intended only for the individual to whom it is addressed and may contain information that is privileged, confidential, or exempt from disclosure under applicable law. If you have received this facsimile in error, please notify the sender immediately by telephone (collect), and return the original message by first-class mail to the above address.

541931_1